Fact CheckerSign in

NCT02490735Not yet recruitingPhase 2

CIK in Treating Patients With Esophageal Cancer

A Randomized Controlled Study of Cytokine-induced Killer Cells (CIK) Treatment in Patients With Staging Ⅰ-Ⅲ of Esophageal Carcinoma

Source: ClinicalTrials.gov · Last updated 7 Jul 2015 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Chemotherapy is the main treatment method for patients with Esophageal Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from growing. A series of studies reported that cytokine-induced killer cells (CIK) have a broad anti-tumor spectrum. The investigators suppose that CIK will improve the prognosis. Combining chemotherapy with biological therapy may kill more tumor cells. In this study, the patients will be treated with CIK cells after chemotherapy. The purpose of this study is to evaluate the efficacy of CIK for Esophageal Cancer.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
2000 (estimated)
First submitted
2 Jul 2015
Start date
Aug 2015
Primary completion date
Aug 2040
Lead sponsor
The First People's Hospital of Changzhou
NCT number
NCT02490735

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 2000
  • From Aug 2015 to the primary completion date, Aug 2040
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients with uncontrolled infection; underlying disease that was severe or life-threatening;
  • Patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment;
  • Patients with active tuberculosis (highly positive skin tests allowed if no active disease);
  • Patients with disease that would preclude general anesthesia;
  • Patients with active intractable or uncontrollable infection.

Other

  • Patients who had distant metastases by imaging studies;
  • Patients who were lactating;
  • ECOG perform status ≥ 2;
  • Patients who are pregnant or nursing;

Who the study is looking for

  • Patients histologically confirmed esophageal carcinoma;
  • Patients with staging I-III of esophageal carcinoma;
  • Patients who had completed chemotherapy;
  • Patients who have a life expectancy of at least 12 weeks;
  • Eastern Cooperative Oncology Group (ECOG) performance status was 0-1;
  • The bone marrow functioned normally (WBC\>4.0×10\^9/L, Hb\>120 g/L, Platelet(PLT)\>100×10\^9/L);
  • The ECG results were normal, and the liver and kidney were functional.

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.